Discontinuation of renin-angiotensin system inhibitors during the early stage of the COVID-19 pandemic.
Paul MuntnerKathryn FotiZhixin WangChibuike J AlanaemeEunhee ChoiAdam P BressDaichi ShimboIan KronishPublished in: American journal of hypertension (2023)
There was no evidence of an increase in RAS inhibitor discontinuation during the early stage of the COVID-19 pandemic.